Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer

Jisup Kim, Sinae Kim, Hye Sun Lee, Wookyeom Yang, Hanbyoul Cho, Doo Byung Chay, Seong Jin Cho, Soonwon Hong, Jae Hoon Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalGynecologic Oncology
Volume149
Issue number2
DOIs
Publication statusPublished - 2018 May

Fingerprint

Programmed Cell Death 1 Receptor
Endometrial Neoplasms
Ligands
Neoplasms
Disease-Free Survival
Cell Death
Immunohistochemistry
CD274 Antigen
Tumor Microenvironment
Survival
Proportional Hazards Models
Microsatellite Repeats

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Kim, Jisup ; Kim, Sinae ; Lee, Hye Sun ; Yang, Wookyeom ; Cho, Hanbyoul ; Chay, Doo Byung ; Cho, Seong Jin ; Hong, Soonwon ; Kim, Jae Hoon. / Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. In: Gynecologic Oncology. 2018 ; Vol. 149, No. 2. pp. 381-387.
@article{9626f38e915b4e77be265de889a811cc,
title = "Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer",
abstract = "Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.",
author = "Jisup Kim and Sinae Kim and Lee, {Hye Sun} and Wookyeom Yang and Hanbyoul Cho and Chay, {Doo Byung} and Cho, {Seong Jin} and Soonwon Hong and Kim, {Jae Hoon}",
year = "2018",
month = "5",
doi = "10.1016/j.ygyno.2018.02.013",
language = "English",
volume = "149",
pages = "381--387",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. / Kim, Jisup; Kim, Sinae; Lee, Hye Sun; Yang, Wookyeom; Cho, Hanbyoul; Chay, Doo Byung; Cho, Seong Jin; Hong, Soonwon; Kim, Jae Hoon.

In: Gynecologic Oncology, Vol. 149, No. 2, 05.2018, p. 381-387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer

AU - Kim, Jisup

AU - Kim, Sinae

AU - Lee, Hye Sun

AU - Yang, Wookyeom

AU - Cho, Hanbyoul

AU - Chay, Doo Byung

AU - Cho, Seong Jin

AU - Hong, Soonwon

AU - Kim, Jae Hoon

PY - 2018/5

Y1 - 2018/5

N2 - Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

AB - Objective: Monoclonal antibodies targeting programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) demonstrated promising clinical response. The predictive/prognostic value of PD-1/PD-L1 immunohistochemistry (IHC) has been evaluated in many cancer types. However, the prognostic value of PD-1/PD-L1 IHC has not been evaluated in endometrial cancer. Methods: We conducted a retrospective study to quantify the IHC CD8, PD-1, and PD-L1 expressions in immune cells at center of tumor (CT), invasive margin (IM), and/or tumor cell in 183 primary endometrial cancer samples from a single cohort, followed by their reciprocal combinations, including compartmental differences, and correlated them with overall survival (OS) and progression-free survival (PFS). Results: In repeated Cox multivariable models adjusted by clinicoimmunopathologic factors, high CT-PD-L1 was an independent adverse prognostic factor for PFS in all patients and in the microsatellite-stable subgroup. Immune marker ratios revealed independently shorter PFS for high CT-PD-L1/CT-CD8 and CT-PD-L1/CT-PD-1 ratios. Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-L1 revealed significantly different survival among groups. Conclusions: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=85044123382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044123382&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.02.013

DO - 10.1016/j.ygyno.2018.02.013

M3 - Article

C2 - 29572029

AN - SCOPUS:85044123382

VL - 149

SP - 381

EP - 387

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -